The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform

Hatice Uslu - One of the best experts on this subject based on the ideXlab platform.

  • Compensatory hypertrophy of the Left Liver Lobe: confused with abdominal infection on Tc-99m HMPAO leukocyte imaging.
    Clinical nuclear medicine, 2003
    Co-Authors: Mustafa Yildirim, Erhan Varoglu, Omer Onbas, Suat Eren, Mehmet Derya Onuk, Hatice Uslu
    Abstract:

    Radionuclide-labeled leukocyte imaging is a useful method for assessing various aspects of inflammatory bowel disease. The accuracy of Tc-99m HMPAO-labeled leukocyte imaging has exceeded that of conventional radiologic and endoscopic techniques. The spleen, Liver, bone marrow, kidneys, bowel, bladder, and major blood vessels are normally visualized on tagged leukocyte scintigraphy. The time to image Tc-99m HMPAO-labeled leukocytes depends, in part, on the type and location of possible infection. Four-hour imaging helps to differentiate physiologic early hepatic uptake from abnormally increased uptake seen with sepsis. Focal collections of inflamed peritoneal fluid or sites of focal bowel inflammation can be mistaken for abscess. The authors report excessive compensatory hypertrophy of the Left Lobe of the Liver on ultrasonography, computed tomography, and labeled leukocyte scintigraphy. Scintigraphic findings could be confused with abdominal infection with possible inflammatory bowel disease.

L.n. Boucher - One of the best experts on this subject based on the ideXlab platform.

  • Baseline Left portal vein and Left Liver Lobe size predicts hypertrophy of the Left Liver Lobe after right portal vein embolization
    Journal of Vascular and Interventional Radiology, 2013
    Co-Authors: S. Patel, E. Wikholm, L.n. Boucher
    Abstract:

    Purpose Postoperative Liver failure is a concern for patients who undergo partial hepatectomy for malignant Liver lesions. Selective portal vein embolization (PVE) aims to increase the volume of the future Liver remnant prior to resection. Hypertrophy of the non-malignant segments of Liver following PVE is variable. Our objective was to determine whether baseline portal vein and Liver size assessed on computed tomography (CT) can predict the degree of hypertrophy of the Liver Lobe following PVE. Materials and Methods A retrospective cohort study of adult patients who underwent right PVE prior to partial hepatectomy at a single university hospital was undertaken. Patients who had prior resections, prior embolization, had Left portal vein or bilateral selective embolization were excluded. Patients were identified from the Liver cancer database and PACS. All patients had a CT scan before and after PVE. The cross-sectional area of the main and Left portal veins on pre and post-embolization CT were assessed within 1cm of the bifurcation. Volumetric measurements of the Left Liver Lobe on all pre and post-embolization scans was performed. The Left Lobe was defined as segments 1, 2, 3, 4a and 4b. Data was analysed by linear regression and is expressed as mean (SD) or as stated. Results Fifty-four patients who met our inclusion criteria underwent first time PVE between 2004 and 2011. Fifty-one (94%) patients had colorectal metastases and the mean age of patients was 61 (10) years. The mean time from baseline CT to PVE was 55 (40.5) days and from PVE to post-embolisation CT was 27 (15.5) days. Baseline Left portal vein and Left Liver Lobe size were the only significant predictors of post PVE Left Liver Lobe hypertrophy. Every mm 2 increase in baseline Left portal vein diameter predicted a 2 cm 3 increase in post PVE Left Liver Lobe size (B = 2.02) (SE: 0.82, p = 0.017). Conversely every cm 3 increase in baseline Left Liver Lobe size predicted a 0.05% reduction in percent increase of Left Liver Lobe size post PVE (B = −0.05) (SE: 0.02, p = 0.002). Conclusion Baseline Left portal vein and Left Liver Lobe size predicts post PVE Left Lobe size in this small cohort. Our findings require validation in larger cohorts derived from multiple centres.

Vincent Vandecaveye - One of the best experts on this subject based on the ideXlab platform.

Boris Radeleff - One of the best experts on this subject based on the ideXlab platform.

  • Portal vein embolization using a Histoacryl/Lipiodol mixture before right Liver resection.
    Digestive Surgery, 2012
    Co-Authors: Nadine Bellemann, Ulrike Stampfl, Christof M. Sommer, Hans-ulrich Kauczor, Peter Schemmer, Boris Radeleff
    Abstract:

    Purpose: The purpose of this retrospective study was to evaluate the efficacy and safety of percutaneous transhepatic portal vein embolization (PVE) of the right Liver Lobe using Histoacryl/Lipiodol mixture to induce contralateral Liver hypertrophy before right-sided (or extended right-sided) hepatectomy in patients with primarily unresectable Liver tumors. Methods: Twenty-one patients (9 females and 12 males) underwent PVE due to an insufficient future Liver remnant; 17 showed Liver metastases and 4 suffered from biliary cancer. Imaging was performed prior to and 4 weeks after PVE. Surgery was scheduled for 1 week after a CT or MRI control. The primary study end point was technical success, defined as complete angiographical occlusion of the portal vein. The secondary study end point was evaluation of Liver hypertrophy by CT and MRI volumetry and transfer to operability. Results: In all the patients, PVE could be performed with a with a Histoacryl/Lipiodol mixture (n = 20) or a Histoacryl/ Lipiodol mixture with microcoils (n = 1). No procedure-related complications occurred. The volume of the Left Liver Lobe increased significantly (p < 0.0001) by 28% from a mean of 549 ml to 709 ml. Eighteen of twenty-one patients (85.7%) could be transferred to surgery, and the intended resection could be performed as planned in 13/18 (72.3%) patients. Conclusion: Preoperative right-sided PVE using a Histoacryl/Lipiodol mixture is a safe technique and achieves a sufficient hypertrophy of the future Liver remnant in the Left Liver Lobe.

T.m. Van Gulik - One of the best experts on this subject based on the ideXlab platform.